India’s weight-loss drug revolution could go global

On Friday (13 March), the patent on semaglutide — the molecule behind Danish drugmaker Novo Nordisk’s blockbuster weight-loss drugs Wegovy and Ozempic — expires in the country

from The Business Standard https://ift.tt/QXWVEv1